menu
    • menu
    [{"orgOrder":0,"company":"Hutchmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Inflammation pathogenesis (IP)||Tumor necrosis factor; Interleukin-1 beta; Interleukin-6; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Undisclosed"},{"orgOrder":0,"company":"Hutchmed","sponsor":"Nutrition Science Partners","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"HONG KONG","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Inflammation pathogenesis (IP)||Tumor necrosis factor; Interleukin-1 beta; Interleukin-6; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Hutchmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hutchmed \/ Nutrition Science Partners","highestDevelopmentStatusID":"10","companyTruncated":"Hutchmed \/ Nutrition Science Partners"},{"orgOrder":0,"company":"Innobioscience","sponsor":"Pontificia Universidad Catolica de Chile | University of Chile | Universidad Austral de Chile","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Tumor necrosis factor; Interleukin-1 beta; Interleukin-6; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Innobioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Innobioscience \/ Pontificia Universidad Catolica de Chile | University of Chile | Universidad Austral de Chile","highestDevelopmentStatusID":"7","companyTruncated":"Innobioscience \/ Pontificia Universidad Catolica de Chile | University of Chile | Universidad Austral de Chile"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Europharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Andrographolide

    Menu

    Andrographolide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Europharma

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Andrographolide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of an Adaptogenic Extract on Electrical Activity of the Brain in Elderly Subjects With Cognitive Impai...

                            Details : Andrographis is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cognitive Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 19, 2018

                            Lead Product(s) : Andrographolide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innobioscience

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Innobioscience

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Andrographolide

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pontificia Universidad Catolica de Chile | University of Chile | Universidad Austral de Chile

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS

                            Details : Andrographolide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Multiple Sclerosis, Chronic Progressive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2014

                            Lead Product(s) : Andrographolide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pontificia Universidad Catolica de Chile | University of Chile | Universidad Austral de Chile

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hutchmed

                            Hong Kong arrow
                            BOS Manchester
                            Not Confirmed

                            Hutchmed

                            Hong Kong arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Andrographolide

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Nutrition Science Partners

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis

                            Details : HMPL-004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 20, 2013

                            Lead Product(s) : Andrographolide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Nutrition Science Partners

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hutchmed

                            Hong Kong arrow
                            BOS Manchester
                            Not Confirmed

                            Hutchmed

                            Hong Kong arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Andrographolide

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

                            Details : HMPL-004 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2013

                            Lead Product(s) : Andrographolide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth